On 27th - 28th February 2020, Albumedix will be attending the Cell Therapy Manufacturing ASIA conference in Kyoto, Japan.

Albumedix attended the International Pharmaceutical Excipients Council (IPEC) Annual Forum and AGM in Aix-en-Provence, France earlier this month.

Back from Phacilitate conference in Miami, we reflect on the exciting trends and developments presented and cannot wait for what 2020 will bring!

Albumedix has attended PepTalk for many years, and as the world of biopharmaceuticals expands towards more complex entities, albumin will always play a role in the stabilisation of the most challenging APIs. As an example of albumin’s potential in stabilising difficult biopharmaceuticals, we have presented the results obtained for glucagon , a notoriously insoluble and unstable peptide. Albumin was not only able to allow the solubilisation of this APIs in a close-to-physiological conditions, where the peptide is insoluble, but also protected it from chemical and physical degradation in accelerated stability tests.

In December, Albumedix held a 'Capping off Ceremony' to celebrate the brand new, four-storey manufacturing plant extension being confirmed as watertight!

Our Market Development Team within Albumedix were looking to carry out an extensive market analysis project into one of the many albumin application areas; in order to obtain information and challenge our current perceptions. Incorporating two postgraduate students into this project allowed us to make quick progress and benefit from an expert external perspective simultaneously.

May 8th marked a big day in Albumedix’s history. Holding a traditional ground-breaking ceremony; our workforce, builders and contractors all gathered to watch Peter Rosholm (Chief Executive Officer) and Stuart Woodward (Chief Manufacturing Officer) take the first official step towards the company’s expansion.